Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis
about
Stenotrophomonas maltophilia: an emerging global opportunistic pathogenAchromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.The changing microbial epidemiology in cystic fibrosis.Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence.Clinical significance of microbial infection and adaptation in cystic fibrosis.Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.Infection control in cystic fibrosis.Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.Genetic Adaptation of Achromobacter sp. during Persistence in the Lungs of Cystic Fibrosis PatientsEpidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.Isolation of infectious cystic fibrosis patients: results of a systematic review.Pseudobacteremia outbreak of biofilm-forming Achromobacter xylosoxidans - environmental transmission.Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.Long-Term Rasamsonia argillacea Complex Species Colonization Revealed by PCR Amplification of Repetitive DNA Sequences in Cystic Fibrosis PatientsFluorescence in situ hybridization for rapid identification of Achromobacter xylosoxidans and Alcaligenes faecalis recovered from cystic fibrosis patients.Clinical Features, Antibiotic Susceptibility Profiles, and Outcomes of Infectious Keratitis Caused by Achromobacter xylosoxidans.Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.Infection prevention and control guideline for cystic fibrosis: 2013 update.A Stenotrophomonas maltophilia multilocus sequence typing scheme for inferring population structure.Development of rapid phenotypic system for the identification of Gram-negative oxidase-positive bacilli in resource-limited settings.Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosis patients.Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.Molecular Characterization of Stenotrophomonas maltophilia isolates from cystic fibrosis patients and the hospital environment.Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis.
P2860
Q26995336-2E62C6CE-8851-4995-861D-F509486E7EFAQ33769610-5BC0C524-835D-46C6-B8D7-A910D03F29AFQ33825634-0498F148-C1E7-43E2-AA8B-28C9EF23C082Q33950924-5B2C9DBC-97AD-447D-BC15-5C092E45629FQ34491552-458B5134-510B-497A-B27E-76EFB78E1888Q35536357-95DF1F2A-E97F-4DD6-A310-C9FE344EF5D7Q35545544-FBC40A78-0FC1-4A9D-92D4-4DC667DB972DQ35627661-E427F08F-59DA-4C2F-93CF-4DC75D5328D4Q35757359-DA864B6D-E55F-4EA1-AA4D-25F60811BB78Q36061478-EA306197-22A5-4D74-8184-88D1553F2473Q36112367-248680B9-1A80-4DBE-ACDD-73FF75240E18Q36166643-D8CC1B30-DA22-43C3-AA95-7E28DDE15B38Q36670892-58340F21-1C39-4F79-8FAF-FF551D871B0EQ37026521-7F0CB61F-2854-4C9D-8EBC-09432DBB2F21Q37363443-7B625343-1E62-4806-8832-00FFE6EF2278Q38476154-8091BD51-8486-44AC-897C-0D023A9EDC20Q38779519-98A53DC7-58B6-426D-8172-1FFF92A25EA4Q39697563-A88041C2-FA4B-44E2-B7ED-E817290A5BEBQ40226374-ED8B86CA-87B8-4826-9B8B-165BF4C5BEFBQ42130118-843CAA81-543C-4C9B-9FAF-A8F3FA56474EQ42206103-C1E3FC2C-6A20-490B-8524-9FE997FB759AQ42215131-5A307BB5-B86E-415A-9EA2-6477A0134BF1Q42263622-9E46E5F3-56B3-4FA5-BF45-9475B75F5D98Q42788748-74881A54-CBDA-426B-861C-292019397149Q44248035-A9361850-ECE7-4C38-B3FF-082F93C9F461Q46520702-F86F9B5B-F6FA-456B-B3B0-8726A3D67DC4Q47126542-2D4B67CA-6DD6-47B9-B517-B42D181F69B3Q51669881-24AA8B3E-A6A3-41D7-98F8-6EB07D4819C1Q51708622-EDEC5F39-F84A-41F5-9CBA-353C385FBB34
P2860
Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Use of random amplified polymo ...... patients with cystic fibrosis
@en
Use of random amplified polymo ...... maltophilia and Achromobacter
@nl
type
label
Use of random amplified polymo ...... patients with cystic fibrosis
@en
Use of random amplified polymo ...... maltophilia and Achromobacter
@nl
prefLabel
Use of random amplified polymo ...... patients with cystic fibrosis
@en
Use of random amplified polymo ...... maltophilia and Achromobacter
@nl
P2093
P2860
P1476
Use of random amplified polymo ...... patients with cystic fibrosis
@en
P2093
C D Nguyen
J M Foster
J W Krzewinski
P2860
P304
P356
10.1128/JCM.39.10.3597-3602.2001
P407
P577
2001-10-01T00:00:00Z